 Lexaria Bioscience Corp NASDAQ:LEXX CSE:LXX is expanding its applied research and development RD program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company announced Thursday. The companys hypertension program now consists of five planned studies, three of which were previously announced on February 1 HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1. 